[{"id":"b1bfb829-6051-48a2-8e1d-95a6b089f5de","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038396","created_at":"2023-09-14T14:13:03.466Z","updated_at":"2025-02-25T17:39:19.635Z","phase":"Phase 1/2","brief_title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","source_id_and_acronym":"NCT06038396","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin) • ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-29"},{"id":"c9408395-7b13-44ae-876f-d2fa76c22593","acronym":"","url":"https://clinicaltrials.gov/study/NCT05205850","created_at":"2022-01-25T15:53:35.224Z","updated_at":"2024-07-02T16:35:18.604Z","phase":"Phase 1/2","brief_title":"A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT05205850","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ciletatug vedotin (RC118)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/03/2022","start_date":" 03/03/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-20"},{"id":"c9b51e1f-3400-4df6-8856-b08f7ea1cc7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04914117","created_at":"2021-06-04T14:53:32.830Z","updated_at":"2024-07-02T16:35:45.117Z","phase":"Phase 1","brief_title":"A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours","source_id_and_acronym":"NCT04914117","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ciletatug vedotin (RC118)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 03/11/2023","study_completion_date":" 03/11/2023","last_update_posted":"2023-06-22"}]